About Shandong Sito Bio-technology Company

The company was founded in 2010, with research and development and production of steroidal drug intermediates as its main business, and was successfully listed on the Shenzhen Stock Exchange in 2017. The company is based on the cutting-edge field of biopharmaceuticals. After years of independent research and development and technology introduction, the company pioneered large-scale application of biopharmaceutical technology in the field of steroidal drugs. It is a biomedical high-tech enterprise that applies genetic engineering technology and microbial transformation technology, and specializes in R&D and production of novel steroidal raw materials. After continuous R&D investment and business expansion after listing, the company has now completed the layout of three major segments: intermediates, high-end respiratory specialty APIs, and formulations. The main products are: androstenedione (AD), androstenedione (ADD), 9-hydroxyandrostenedione (9OH-AD), 17α-hydroxyprogesterone derivative (A ring), and dialcohol (BA), developed and produced more than ten high-end intermediates, including medroxyprogesterone (8DM), betamethasone epoxyhydrolysate (DB11), tetradiene (3TR), anekotat acetate (H6), and 499 materials. Corporate honors: High-tech enterprise certificate, Shandong Engineering Laboratory, shortlisted in the fifth batch of green manufacturing lists of the General Office of the Ministry of Industry and Information Technology of Shandong Province, awarded as a leading enterprise in the top ten industrial clusters in Shandong Province, and the subsidiary Sirui Pharmaceutical won the honorary title of Specialized and New Small and Medium Enterprises in Shandong Province, etc.